Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765035 | 0.85 | NPC1 (0.46) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3571320 | 0.81 | KMT2A (0.60) | KMT2AMEN1SMN1; SMN2TDP1NPC1 | |
| SCHEMBL5198772 | 0.81 | SMN1; SMN2 (0.63) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3117145 | 0.78 | CYP2D6 (0.67) | KMT2ACYP2D6CA12CA2CA9 | |
| SCHEMBL27879364 | 0.74 | SMN1; SMN2 (0.38) | KMT2AMEN1SMN1; SMN2TDP1CYP2D6 | |
| SCHEMBL1353584 | 0.74 | LMNA (0.61) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30987846 | 0.73 | CA12 (0.64) | KMT2AMEN1TDP1CYP2D6CA12 | |
| SCHEMBL1356631 | 0.73 | TP53 (0.70) | SMN1; SMN2CA2CA9LMNA | |
| SCHEMBL5200362 | 0.73 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2TDP1NPC1 | |
| SCHEMBL1353592 | 0.72 | PKM (0.55) | NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | claimed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | KMT2A 1587/4885MEN1 3828/4885SMN1; SMN2 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.